Literature DB >> 26331560

Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease.

S Paul1, X Roblin2, L Peyrin-Biroulet3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26331560     DOI： 10.1111/apt.13335

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  5 in total

1.  De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease.

Authors:  Konstantinos Papamichael; Pantelis Karatzas; Gerasimos J Mantzaris
Journal:  J Crohns Colitis       Date:  2015-11-06       Impact factor: 9.071

Review 2.  Use of anti-TNF drug levels to optimise patient management.

Authors:  Konstantinos Papamichael; Adam S Cheifetz
Journal:  Frontline Gastroenterol       Date:  2016-02-26

Review 3.  Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.

Authors:  Laura Martelli; Pablo Olivera; Xavier Roblin; Alain Attar; Laurent Peyrin-Biroulet
Journal:  J Gastroenterol       Date:  2016-09-24       Impact factor: 7.527

Review 4.  Biologic therapies for Crohn's disease: optimising the old and maximising the new.

Authors:  Mark Samaan; Samantha Campbell; Georgina Cunningham; Aravind Gokul Tamilarasan; Peter M Irving; Sara McCartney
Journal:  F1000Res       Date:  2019-07-29

Review 5.  Inflammatory bowel disease: towards a personalized medicine.

Authors:  Mathurin Flamant; Xavier Roblin
Journal:  Therap Adv Gastroenterol       Date:  2018-01-10       Impact factor: 4.409
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.